Immunotoxicity of Therapeutic Antibodies and Nanoparticles

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000527295200003&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1615/CritRevImmunol.2020033236
eISSN
2162-6472
Externe Identifier
  • Clarivate Analytics Document Solution ID: LF3BB
  • PubMed Identifier: 32421979
ISSN
1040-8401
Ausgabe der Veröffentlichung
1
Zeitschrift
CRITICAL REVIEWS IN IMMUNOLOGY
Schlüsselwörter
  • monoclonal antibody
  • nanotherapy
  • immunomodulation
Paginierung
53 - 74
Datum der Veröffentlichung
2020
Status
Published
Titel
Immunotoxicity of Therapeutic Antibodies and Nanoparticles
Sub types
  • Article
Ausgabe der Zeitschrift
40

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Autoren
DOI
10.1615/critrevimmunol.2020033236
ISSN
1040-8401
Ausgabe der Veröffentlichung
1
Zeitschrift
Critical Reviews in Immunology
Sprache
en
Paginierung
53 - 74
Datum der Veröffentlichung
2020
Status
Published
Herausgeber
Begell House
Herausgeber URL
http://dx.doi.org/10.1615/critrevimmunol.2020033236
Datum der Datenerfassung
2020
Titel
Immunotoxicity of Therapeutic Antibodies and Nanoparticles
Ausgabe der Zeitschrift
40

Datenquelle: Crossref

Abstract
Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining more efficient drug design with better tolerability and fewer adverse effects are discussed to ensure improved safety in the engineering of therapeutic antibodies and nanotherapeutics.
Addresses
  • Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany; Hacettepe University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.
Autoren
DOI
10.1615/critrevimmunol.2020033236
Externe Identifier
  • PubMed Identifier: 32421979
Open access
false
ISSN
1040-8401
Ausgabe der Veröffentlichung
1
Zeitschrift
Critical reviews in immunology
Schlüsselwörter
  • Immune System
  • Animals
  • Humans
  • Antibodies
  • Cytotoxicity, Immunologic
  • Drug Design
  • Nanoparticles
  • Immunomodulation
  • Bioengineering
  • Drug-Related Side Effects and Adverse Reactions
Sprache
eng
Medium
Print
Paginierung
53 - 74
Datum der Veröffentlichung
2020
Status
Published
Datum der Datenerfassung
2020
Titel
Immunotoxicity of Therapeutic Antibodies and Nanoparticles.
Sub types
  • Research Support, Non-U.S. Gov't
  • Review
  • Journal Article
Ausgabe der Zeitschrift
40

Datenquelle: Europe PubMed Central

Abstract
Therapeutic antibodies and nanotherapeutic drugs are of great concern due to their widespread use against numerous diseases worldwide. They are frequently used for targeted therapy under the assumption that they cause fewer side effects than nontargeted drugs. Despite their specificity and particular design for therapeutic actions, they might still exhibit unintended adverse effects in the immune system. Immunotoxicity reactions are mediated by immunomodulation, including immunostimulation and immunosuppression. The present review gives an overview on the adverse immunotoxic effects induced by therapeutic antibodies as well as nanotherapeutic drugs. In this context, future methods combining more efficient drug design with better tolerability and fewer adverse effects are discussed to ensure improved safety in the engineering of therapeutic antibodies and nanotherapeutics.
Autoren
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/32421979
DOI
10.1615/CritRevImmunol.2020033236
ISSN
1040-8401
Ausgabe der Veröffentlichung
1
Zeitschrift
Crit Rev Immunol
Schlüsselwörter
  • Animals
  • Antibodies
  • Bioengineering
  • Cytotoxicity, Immunologic
  • Drug Design
  • Drug-Related Side Effects and Adverse Reactions
  • Humans
  • Immune System
  • Immunomodulation
  • Nanoparticles
Sprache
eng
Country
United States
Paginierung
53 - 74
PII
15281ffe75123d72,117f594e4b28b2fc
Datum der Veröffentlichung
2020
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2020
Titel
Immunotoxicity of Therapeutic Antibodies and Nanoparticles.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review
Ausgabe der Zeitschrift
40

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge